Prabhjot S. Mundi

Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant state

Gloria V. Echeverria, Zhongqi Ge, Sahil Seth et al. · Science Translational Medicine · 2019 · 298 citations

Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: MAINTAIN Trial

Kevin Kalinsky, Melissa Accordino, Codruța Chiuzan et al. · Journal of Clinical Oncology · 2023 · 169 citations

Precision Targeting with EZH2 and HDAC Inhibitors in Epigenetically Dysregulated Lymphomas

Jennifer Kimberly Lue, Sathyen A. Prabhu, Yuxuan Liu et al. · Clinical Cancer Research · 2019 · 75 citations · Full text

A randomized, phase II trial of fulvestrant or exemestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition (CDK 4/6i) in patients (pts) with unresectable or hormone receptor–positive (HR+), HER2-negative metastatic breast cancer (MBC): MAINTAIN trial.

Kevin Kalinsky, Melissa Accordino, Codruța Chiuzan et al. · Journal of Clinical Oncology · 2022 · 73 citations

Breast Oncology, Cancer Management, Pharmacotherapy +18

Emerging Therapeutic Implications of <i>STK11</i> Mutation: Case Series

Bahar Laderian, Prabhjot S. Mundi, Tito Fojo et al. · The Oncologist · 2020 · 53 citations · Full text